Can a weekly injection tackle both obesity and diabetes?

NCT ID NCT07728318

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This trial investigates whether adding a once-weekly injection of tirzepatide to standard diabetes pills can improve blood sugar control and promote weight loss in obese adults with type 2 diabetes. Over six months, researchers will compare changes in HbA1c and body weight between those receiving tirzepatide plus standard care and those on standard care alone. The study also tracks side effects and patient satisfaction with treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a once-weekly injection of tirzepatide, a dual GIP/GLP-1 receptor agonist, combined with standard oral diabetes medications
What this could lead to
If successful, this could provide a more effective option for managing both blood sugar and weight in obese type 2 diabetes patients, especially in South Asian populations.
What could go wrong
This is a small, 6-month study with 52 participants, so results may not apply broadly. Gastrointestinal side effects are common with tirzepatide, and long-term safety data are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.